Fibrin-PTH is a drug-biologic that promotes bone growth through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and increasing the lifespan of bone-forming cells.
University of California San Diego’s Richard Allen, MD, PhD, principal investigator of the study, treated the first patient.
The phase 2 study is evaluating the technology for both open and minimally invasive surgical techniques.
Fifty patients will be enrolled in the trial, with those treated with local autograft acting as controls.
More articles on biologics:
Meet Elon Musk’s surgical robot
Laser Spine Institute 18 months after closure — What happened to its $56M Tampa HQ?
Vertebral body tethering shows success in the treatment of scoliosis, study finds
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
